Haluk Tezcan MD (He/Him)

PubMed

• 14 citations
  Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors.
  Andrew M. Davis, Wade T. Iams, David Chan, Michael S. Oh, Robert W. Lentz
  Molecular Cancer Therapeutics. 2020-01-01
• 13 citations
  Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients.
  Baruch Brenner, Ravit Geva, Megan P. Rothney, Alexander Beny, Ygael Dror
  Value in Health. 2016-01-01
• 16 citations
  Validation of the 12-Gene Colon Cancer Recurrence Score as a Predictor of Recurrence Risk in Stage II and III Rectal Cancer Patients
  Marlies S. Reimers, Peter J. K. Kuppen, Mark Lee, Margarita Lopatin, Haluk Tezcan
  Journal of the National Cancer Institute. 2014-11-01

Journal Articles

• Validation of the 12-Gene Colon Cancer Recurrence Score as a Predictor of Recurrence Risk in Stage II and III Rectal Cancer Patient  
  Marlies S. Reimers MS, Kuppen PJK, Lee M, Lopatin M, Tezcan H, Putter H, Clark-Langone K, Liefers GJ, Shak S, and  van de Velde CJH, JNCI J Natl Cancer Inst , 1/1/2014
• Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from A...  
  Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, Roach N, Mun Y, Fish S, Flick ED, Dalal D, Grothey A, Oncologist, 1/1/2012
• DNA Methylation in Lung Cancer  
  Tezcan H, NEJM, 1/1/2008
• Limited Stage I and II Follicular Non-Hodgkin’s Lymphoma: The Nebraska Lymphoma Study Group Experience  
  Tezcan H, Vose JM, Bast M et al, Leukemia and Lymphoma, 1/1/1999
• Severe cerebellar swelling and thrombotic thrombocytopenic purpura in allogeneic BMT patients receiving FK506 and high-dose steroids after developing cyclosporine-asso...  
  Tezcan H, Schriber J, Zimmer W et al, Bone Marrow Transplantation, 1/1/1998
• Treatment of acute promyelocytic leukemia in patients presenting at the VGH from 1983 to 1992  
  Tezcan H, Barnett M, Bredeson C et al, Leukemia and Lymphoma, 1/1/1995
• Heparin induced thrombocytopenia after bone marrow transplantation - report of two cases  
  Tezcan AZ, Tezcan H, Gastineau D, Armitage JO, Haire WD, Bone Marrow Transplantation, 1/1/1994
• Comparison of three different methods for automated classification of cervical cells  
  Palcic B, MacAulay C, Shilen S, Treueniet W, Tezcan H, and Anderson G, Analytical Cellular Pathology, 1/1/1992
• Adoptive Color Basis Transformation  
  MacAulay C, Tezcan H and Palcic B, Analytical and Quantitative Cytology, 1/1/1989
• Join now to see all

Books/Book Chapters

• Cancer Patient Follow-Up 
  Chapter: Breast cancer follow-up procedures 
  Edge S, Arredendo M, Tezcan H, Levine EGEditors: Johnson FE and Virgo KS.Mosby-Yearbook, Inc, St. Louis, MO1997

Abstracts/Posters

• Next Generation Sequencing of DNA from Urine detects multiple bladder tumor-derived alterations and additional changes that suggest tumor heterogeneity
  Abramson R, Alexander G, Beasley EM, Collin F, Crager M PhD, Dei Rossi A, Dorado J, Friedman A, Gibb B, Jeong J, Jones C, C. Ku CJ, Ma Y, Morlan J, Qu K, Rao A, Scott ..., SUO, Bethesda, MD, 1/1/2014
• Global quantitative measures using next-generation sequencing for breast cancer presence outperform individual tumor markets in plasma
  Beasley EM, Abramson RD, Alexander GE, Chan D, Bradley K, Collin F, Crager M, Dei Rossi A, Dorado J, Friedman A, Gibb WJ, Jeong J, Jones C, Ku CJ, Ma Y, Morlan J, Qu K..., SABCS, 1/1/2014
• Prospective evaluation of a 12-gene assay on patient treatment decisions and physician confidence in mismatch repair-proficient (MMR-P) stage IIa colon cancer patients
  Alberts SR, Renfro LA, Lopatin M, Tezcan H, Sloan J, Chao C, Lee M, ASCO GI Symposium, 1/1/2014
• The 12-gene colon cancer assay: summary of clinical evidence
  Burke E, Tezcan H, Lopatin M, Clark-Langone K, Lee M, Shak S, Sing A, ASCO GI Symposium, 1/1/2014
• Validation of the 12-­gene colon cancer recurrence score assay as a predictor of recurrence risk in stage II and III rectal cancer patients
  Reimers MS, Kuppen PJK, Lee M, Tezcan H, Putter H, Lopatin M, Clark-­Langone K, Liefers GJ, Shak S(2), van de Velde CJH, EJC, 1/1/2013
• Treatment Patterns and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Initially Treated with FOLFOX–Bevacizumab or FOLFIRI–Bevacizumab: Results From A...
  Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, Roach N, Mun Y, Fish S, Flick ED, Dalal D, Grothey A, Oncologist, 1/1/2012
• Phase II results of tasisulam-sodium in previously treated patients with metastatic breast cancer
  LS Schwartzberg, HH Soliman, AK Conlin, CO Ruud, H Tezcan, J Bromund, K Hogeterp, C Kaiser, J Chen, K Chow, RL Ilaria, K Miller, ASCO Breast Cancer Symposium, 1/1/2012
• Z-ACT1: Zometa Combined with Standard Therapy in Patients with Metastatic Breast Cancer Further Decreases the Proportion of Patients with CTC Counts of 5 or above
  Brufsky A, Beck J, Dakhil S, Hallmeyer S, Tezcan H, Yardley D, Tran D, Warsi G, Culver K, SABCS, San Antonio, TX, 1/1/2011
• Microdeletions at Apparently Balanced Translocation Breakpoints Are Biomarkers for Heightened Genomic Instability in Patients with Non-MLL Acute Myeloid Leukemia
  RA Schultz, TC Brown, LJC, M Wall, J Schoumans, JY Han, U Surti, E Crawford, SD Stewart, RR Tubbs, JR Cook, AM Gruver, A Dean, H Tezcan, A Furrow, LG Shaffer, BC Ballif, ASH, 1/1/2011
• Similarities in treatment (Tx) patterns and clinical outcomes (CO) in patients (pts) with metastatic colorectal cancer (mCRC) initially treated with FOLFOX/BV or FOLFI...
  J.C. Bendell, T.S. Bekaii-Saab, A.L. Cohn, H. Hurwitz, M. Kozloff, H. Tezcan, S. Feng, E.D. Flick, A. Sing, A Grothey, J Clin Oncol, 1/1/2011
• Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal (mCRC) in ARIES an observational cohort stu...
  M. Kozloff, T.S. Bekaii-Saab, J.C. Bendell, A.L. Cohn, H. Hurwitz, N. Roach, H. Tezcan, S. Fish, E.D. Flick, Y. Mun, D. Dalal, A. Grothey, J Clin Oncol, 1/1/2011
• Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS)
  T. S. Bekaii-Saab, J. C. Bendell, A. L. Cohn, H. Hurwitz, M. Kozloff, N. Roach, H. Tezcan, S. Feng, A. Sing, A. Grothey, J Clin Oncol, 1/1/2010
• DNA Methylation in Lung Cancer
  Toyooka S, Matsuo K, Gazdar AF, Park IK, Riaz N, Tezcan H, Brock MV, Herman JG, Baylin SB, N Engl J Med, 1/5/2008
• Management and outcome of elderly patients (70 and over) with early stage breast cancer in rural community setting
  McCoy JA, McCoy MM, Tezcan AZ, Tezcan H, SABCS, San Antonio, TX, 1/1/2007
• Weekly Chemotherapy with Docetaxel, Carboplatin and Gemcitabine in Stage IIIB and IV Non-small Cell Lung Cancer (NSCLC). A Phase II Study
  Tezcan H, Grosset AB, Tezcan AZ and Sims R, American Society of Clinical Oncology, 1/1/2002
• Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirma...
  A. L. Cohn, T. Bekaii-Saab, J. C. Bendell, H. Hurwitz, M. Kozloff, N. Roach, H. Tezcan, S. Feng, A. Sing, A. Grothey, J Clin Oncol, 1/1/2002
• Breast Cancer Management in a Rural community: Standards of Care and How to Improve?
  Wright S, Tezcan AZ, Sims R, Grosset AB and Tezcan H, Northwest Cancer Conference, Spokane, WA, 1/1/1999
• Thiotepa-associated cardiomyopathy during hematopoietic stem cell transplantation
  Alidina A, Baer MR, Bernstein S, Bernstein Z, Christiansen N, Czuczman M, Schriber J, Slack J, Spangenthal T, Tezcan H, Wetzler W, Cooper M, Milk B, Swinnich D, Ford L..., Blood, 1/1/1997
• Phase II clinical trial of OKT3 for acute graft-versus-host disease (GVHD) prophylaxis in allogeneic BMT
  Alam A, Baer MR, Bernstein S, Bernstein Z, Christiansen N, Czuczman M, Schriber J, Slack J, Tezcan H, Wetzler W, Cooper M, Milk B, Ford L, Herzig G and McCarthy P, Blood, 1/1/1997
• Murine monoclonal antibody directed against CD3 (OKT3) is an effective treatment for moderate (grade II) but not for severe (grade III or IV) steroid resistant graft v...
  Schriber JR, Baer MR, Christiansen NP, McCarthy PL, Slack JL, Tezcan H, Wetzler M and Herzig GP, Blood, 1/1/1996
• A randomized phase II trial comparing heparin + prostaglandin E1 to prevent hepatotoxicity following BMT: preliminary results
  Schriber JR, Milk BJ, Baer MR, Christiansen NP, McCarthy PL, Slack JL, Tezcan H, Wetzler M and Herzig GP, Blood, 1/1/1996
• Efficacy of hemodialysis after allogeneic BMT
  Schriber JR, Mookerjee BK, Baer MR, Christiansen NP, McCarthy PL, Slack JL, Tezcan H, Wetzler M and Herzig GP, Blood, 1/1/1996
• Secondary treatment of acute graft-versus host disease with anti-CD5 Ricin A chain immunotoxin: a single institute experience
  Tezcan H, Bardy P, Barnett MJ et al, ASBMT meeting, Keystone, CO, 1/1/1995
• Limited stage of follicular non-Hodgkin’s lymphoma: the Nebraska Lymphoma Study Group (NLSG) experience
  Tezcan H, Vose J, Bast M et al, 36th Annual Meeting of ASH, Blood, 1/1/1994
• Avascular necrosis of bone is a frequent complication of unrelated donor bone marrow transplantation
  Tezcan H, Bredeson C, Barnett MJ et al, Blood, 1/1/1993
• Join now to see all